ROCKVILLE, MD and SHENZHEN, CHINA, March 16, 2023— HighTide Therapeutics Inc. (“HighTide”), today announced that Dr. Liping Liu, founder and CEO of HighTide, was selected for the EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2023.

The EY Entrepreneurial Winning Women™ Asia-Pacific program is one of the world's most prestigious awards for female entrepreneurs who are making a difference. In this selection, 15 outstanding female entrepreneurial leaders stood out and won this honor. As one of the five outstanding female entrepreneurs from mainland China, Dr. Liping Liu joins the EY Entrepreneurial Winning Women™ Asia-Pacific Program with 10 outstanding female entrepreneurs from 5 countries.

EY Entrepreneurial Winning Women™ Asia-Pacific Program is part of the EY Global Project of Entrepreneurial Winning Women™, which has been held successfully for eight consecutive years. The program has recognized over 130 female entrepreneurs for having extraordinary vision, profound insight, and creative and innovative spirit in leading and fostering enterprise growth.

During the past year, businesses around the world faced enormous challenges, and female entrepreneurs and leaders have demonstrated resilience, wisdom and power in overcoming difficulties and leading sustainable expansion.

“I am honored to be selected for the EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2023,” said Dr. Liping Liu. “At HighTide, my team and I firmly believe that drug research and development should address unmet medical needs globally, and we have been focusing on chronic diseases with multiple comorbidities. Currently, we are actively advancing several programs to late-stage clinical development.”

About HighTide
HighTide Therapeutics Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs.  The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).  HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC.  In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

For more information, please visit www.hightidetx.com, Contact: pr@hightidetx.com